Event Details
January 01, 2004
Description
Mr. Hugin spoke at an investor conference, calling Thalomid the company's 'financial engine'.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| Mr. Hugin | person | 19 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_028419.jpg
This document, from a House Oversight file, details the business practices of the pharmaceutical company Celgene concerning its drugs Thalomid and Revlimid between 2000 and 2017. It outlines allegations of improper 'off-label' marketing, significant price increases, and aggressive strategies to extend its patent monopoly and block competition from generic drug makers. The document includes quotes from a Celgene executive, a federal regulatory agency, and a generic drug industry representative.
Related Events
Events with shared participants
Mr. Hugin arrived at Celgene, which was struggling to profit from its only marketed drug, Thalomid.
1999-01-01 • New Jersey
Mr. Hugin arrived at Celgene while the company was struggling to profit from its only drug, Thalomid.
1999-06-01 • New Jersey
Mr. Hugin, a managing director at J.P. Morgan, was hired by Celgene as a top executive.
Date unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event